gc012f,tocilizumab
roche,gracell,lightchain biosciences
['mmsm', 'toci', 'gc012f ', 'light chain']
gc012f for newly diagnosed high risk mm. 69% extramedullary dz; remarkable that crs rate was so low (25%). now we have to see how long this therapy lasts, but intriguing as we see other car t-cell approaches moving to the frontline setting in randomized designs. #ash22 #mmsm 
Asst Professor at University of Chicago, specializing in (vanquishing) plasma cell disorders. I tweet about: Myeloma & MRD. https://t.co/mPeWg1QRrW